Gyre Therapeutics (NASDAQ:GYRE) Sets New 1-Year Low - Time to Sell?

Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) shares reached a new 52-week low on Tuesday . The stock traded as low as $7.00 and last traded at $7.72, with a volume of 411920 shares changing hands. The stock had previously closed at $9.11.

Wall Street Analyst Weigh In

Separately, Noble Financial started coverage on shares of Gyre Therapeutics in a report on Tuesday, March 11th. They issued an "outperform" rating on the stock.

Gyre Therapeutics Price Performance

The company has a market cap of $647.80 million, a PE ratio of 138.40 and a beta of 1.93. The business has a 50-day moving average of $10.77 and a 200 day moving average of $11.84.

Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) last posted its quarterly earnings data on Monday, March 17th. The company reported $0.01 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.04 by ($0.03). Gyre Therapeutics had a negative return on equity of 118.43% and a negative net margin of 84.57%. The business had revenue of $27.87 million during the quarter, compared to analysts' expectations of $23.50 million.

Institutional Investors Weigh In On Gyre Therapeutics

Hedge funds have recently modified their holdings of the business. SBI Securities Co. Ltd. purchased a new position in Gyre Therapeutics during the fourth quarter valued at $1,225,000. Charles Schwab Investment Management Inc. grew its stake in shares of Gyre Therapeutics by 392.2% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 113,648 shares of the company's stock valued at $1,425,000 after acquiring an additional 90,557 shares during the period. Geode Capital Management LLC raised its stake in Gyre Therapeutics by 16.9% during the 3rd quarter. Geode Capital Management LLC now owns 303,647 shares of the company's stock worth $3,808,000 after acquiring an additional 43,840 shares during the period. Northern Trust Corp lifted its holdings in Gyre Therapeutics by 9.1% during the fourth quarter. Northern Trust Corp now owns 103,382 shares of the company's stock valued at $1,251,000 after purchasing an additional 8,624 shares in the last quarter. Finally, State Street Corp boosted its position in shares of Gyre Therapeutics by 8.8% in the third quarter. State Street Corp now owns 104,490 shares of the company's stock worth $1,310,000 after purchasing an additional 8,412 shares during the period. Institutional investors own 23.99% of the company's stock.

Remove Ads

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.